Renal Clear Cell

Localized / Metastatic / Locally Advanced

T1b or greater (has not spread beyond the kidney)

No Prior Systematic Therapy

Prior Systematic Therapy

No prior VEGF. Up to 1 prior cytokine or immune checkpoint inhibitor

Track 2: Prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4

Progression on anti-PD-1/PD-L1 mAb monotherapy or in combo w/ other therapies

Nephrectomy Candidate

Papillary Renal Carcinoma

No prior VEGF. Up to 1 prior cytokine or immune checkpoint inhibitor

Track 2: Prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4

Progression on anti-PD-1/PD-L1 mAb monotherapy or in combo w/ other therapies

TBD

TBD

TBD

TBD

Key

Open for Enrollment
In Development
Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

CROSS-DISEASE TRIALS

IRB# 19992
EAY 131 (MATCH)

IRB# 18084
S1609 (DART)

IRB# 23201
ALLN-177-302

IRB# 22193
MK6482-012: An Open label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First Line Treatment in Participants with Advanced cCRCC

IRB# 22759
S1931: Phase III Trial of Immunotherap y-based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE)

IRB# 19991
A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed By Nivolumab vs VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDTREEE)

IRB# 13619
NKT2152-101: A Phase 1/2, Open Label Dose-Escalation and Expansion Trial of NKT2152, An Orally Administered HIF2α Inhibitor, To Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinoma

IRB# 19991
A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed By Nivolumab vs VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDTREEE)

IRB# 22759
S1931: Phase III Trial of Immunotherap y-based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE)

13-JUL-2022